Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| History, 21st Century | 19 | 2021 | 1849 | 2.05 | Why? |
| History, 20th Century | 18 | 2021 | 1282 | 2.05 | Why? |
| Environmental Health | 3 | 2018 | 203 | 1.70 | Why? |
| Sexual Health | 3 | 2019 | 419 | 1.49 | Why? |
| Neurology | 4 | 2018 | 1613 | 1.24 | Why? |
| HIV Infections | 9 | 2020 | 11620 | 1.09 | Why? |
| Acquired Immunodeficiency Syndrome | 2 | 2019 | 533 | 0.96 | Why? |
| Vaping | 2 | 2019 | 436 | 0.96 | Why? |
| AIDS Vaccines | 2 | 2017 | 452 | 0.94 | Why? |
| Mental Fatigue | 1 | 2021 | 48 | 0.87 | Why? |
| Spinocerebellar Ataxias | 1 | 2018 | 20 | 0.75 | Why? |
| Mycoplasma genitalium | 1 | 2018 | 30 | 0.75 | Why? |
| Population | 1 | 2019 | 114 | 0.75 | Why? |
| Homosexuality, Male | 2 | 2018 | 1158 | 0.75 | Why? |
| Strategic Stockpile | 1 | 2020 | 120 | 0.74 | Why? |
| Foundations | 1 | 2019 | 88 | 0.73 | Why? |
| Axons | 1 | 2018 | 73 | 0.73 | Why? |
| Right to Die | 1 | 2018 | 13 | 0.73 | Why? |
| Mycoplasma Infections | 1 | 2018 | 65 | 0.72 | Why? |
| Human Experimentation | 1 | 2020 | 146 | 0.72 | Why? |
| Fatigue Syndrome, Chronic | 1 | 2021 | 160 | 0.71 | Why? |
| Biostatistics | 1 | 2019 | 116 | 0.70 | Why? |
| Pest Control | 1 | 2017 | 26 | 0.69 | Why? |
| Police | 1 | 2020 | 243 | 0.67 | Why? |
| Organizational Objectives | 1 | 2018 | 180 | 0.66 | Why? |
| Social Control, Formal | 1 | 2019 | 165 | 0.65 | Why? |
| Chlamydia Infections | 1 | 2019 | 248 | 0.64 | Why? |
| Extensively Drug-Resistant Tuberculosis | 1 | 2017 | 87 | 0.63 | Why? |
| Diarylquinolines | 1 | 2017 | 90 | 0.63 | Why? |
| Social Support | 2 | 2021 | 3183 | 0.63 | Why? |
| National Institutes of Health (U.S.) | 1 | 2019 | 443 | 0.62 | Why? |
| Carbapenems | 1 | 2019 | 343 | 0.61 | Why? |
| Bone Marrow Transplantation | 1 | 2019 | 343 | 0.60 | Why? |
| Endocrinology | 1 | 2019 | 252 | 0.60 | Why? |
| Government Programs | 1 | 2020 | 512 | 0.60 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.59 | Why? |
| Global Health | 6 | 2020 | 13911 | 0.59 | Why? |
| Remission Induction | 1 | 2019 | 950 | 0.58 | Why? |
| Ovarian Neoplasms | 1 | 2020 | 465 | 0.57 | Why? |
| Tropical Medicine | 1 | 2017 | 237 | 0.57 | Why? |
| Disease Transmission, Infectious | 4 | 2019 | 9044 | 0.56 | Why? |
| Drug Resistance, Microbial | 1 | 2019 | 419 | 0.56 | Why? |
| Electronic Nicotine Delivery Systems | 2 | 2019 | 561 | 0.56 | Why? |
| Immunization Programs | 2 | 2018 | 2006 | 0.56 | Why? |
| Vaccines, DNA | 1 | 2021 | 871 | 0.56 | Why? |
| School Health Services | 1 | 2019 | 294 | 0.56 | Why? |
| Epidemics | 3 | 2019 | 6407 | 0.53 | Why? |
| Federal Government | 1 | 2020 | 562 | 0.52 | Why? |
| Stem Cell Transplantation | 1 | 2019 | 531 | 0.52 | Why? |
| Sexually Transmitted Diseases | 2 | 2019 | 694 | 0.51 | Why? |
| Health Policy | 6 | 2019 | 6242 | 0.51 | Why? |
| Enterobacteriaceae Infections | 1 | 2019 | 529 | 0.50 | Why? |
| Mandatory Programs | 1 | 2017 | 291 | 0.50 | Why? |
| Preventive Health Services | 1 | 2018 | 501 | 0.49 | Why? |
| Neglected Diseases | 1 | 2017 | 381 | 0.49 | Why? |
| Anti-Retroviral Agents | 2 | 2018 | 1099 | 0.49 | Why? |
| Tuberculosis | 2 | 2019 | 2895 | 0.48 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.48 | Why? |
| Papillomavirus Vaccines | 1 | 2018 | 405 | 0.48 | Why? |
| Pediatrics | 2 | 2018 | 2969 | 0.48 | Why? |
| Hematologic Diseases | 1 | 2019 | 614 | 0.47 | Why? |
| Pulmonary Medicine | 1 | 2018 | 706 | 0.44 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.43 | Why? |
| United Kingdom | 9 | 2021 | 18046 | 0.43 | Why? |
| Medical Oncology | 2 | 2020 | 3826 | 0.43 | Why? |
| Australia | 6 | 2020 | 6306 | 0.42 | Why? |
| General Practice | 1 | 2019 | 718 | 0.42 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.41 | Why? |
| Biomedical Research | 4 | 2021 | 5270 | 0.40 | Why? |
| Public Health Administration | 1 | 2018 | 846 | 0.39 | Why? |
| Minority Groups | 1 | 2020 | 1631 | 0.38 | Why? |
| Communicable Disease Control | 4 | 2020 | 29620 | 0.38 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.38 | Why? |
| Health Services Accessibility | 5 | 2020 | 10697 | 0.38 | Why? |
| Public Health | 4 | 2020 | 16359 | 0.38 | Why? |
| Vaccination Refusal | 1 | 2017 | 831 | 0.37 | Why? |
| Homeless Persons | 1 | 2020 | 1171 | 0.37 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.36 | Why? |
| Respiratory Tract Diseases | 1 | 2016 | 1061 | 0.36 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.35 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.35 | Why? |
| Cystic Fibrosis | 1 | 2017 | 1104 | 0.34 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2019 | 1475 | 0.34 | Why? |
| Politics | 1 | 2021 | 1824 | 0.34 | Why? |
| Poverty | 1 | 2019 | 2302 | 0.33 | Why? |
| Alzheimer Disease | 1 | 2017 | 1020 | 0.33 | Why? |
| Rural Population | 1 | 2019 | 2408 | 0.32 | Why? |
| Humans | 50 | 2021 | 930598 | 0.32 | Why? |
| San Francisco | 2 | 2019 | 711 | 0.31 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.31 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.31 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.30 | Why? |
| Epilepsy | 1 | 2018 | 1401 | 0.30 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.29 | Why? |
| HIV-1 | 1 | 2020 | 3365 | 0.29 | Why? |
| Substance-Related Disorders | 1 | 2019 | 2038 | 0.27 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.26 | Why? |
| Lung Diseases | 1 | 2017 | 2361 | 0.26 | Why? |
| HIV | 2 | 2019 | 1116 | 0.23 | Why? |
| Asthma | 2 | 2017 | 4383 | 0.22 | Why? |
| Motion Pictures | 1 | 2020 | 62 | 0.20 | Why? |
| Chlamydia | 1 | 2019 | 47 | 0.20 | Why? |
| Self-Help Groups | 1 | 2021 | 163 | 0.20 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.20 | Why? |
| Physicians | 1 | 2019 | 4214 | 0.20 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.19 | Why? |
| Regional Health Planning | 1 | 2020 | 135 | 0.19 | Why? |
| Malta | 1 | 2018 | 70 | 0.19 | Why? |
| Nicotinic Agonists | 1 | 2019 | 56 | 0.19 | Why? |
| Life Change Events | 1 | 2021 | 208 | 0.19 | Why? |
| Sustainable Growth | 1 | 2017 | 4 | 0.19 | Why? |
| Aminophenols | 1 | 2017 | 22 | 0.18 | Why? |
| Capital Financing | 1 | 2018 | 35 | 0.18 | Why? |
| South America | 1 | 2020 | 565 | 0.18 | Why? |
| Terminally Ill | 1 | 2018 | 40 | 0.18 | Why? |
| Homozygote | 1 | 2019 | 230 | 0.18 | Why? |
| Nervous System Diseases | 1 | 2017 | 4092 | 0.18 | Why? |
| Value of Life | 1 | 2018 | 52 | 0.17 | Why? |
| Portraits as Topic | 1 | 2017 | 19 | 0.17 | Why? |
| Air Pollution | 1 | 2016 | 3504 | 0.17 | Why? |
| Family Relations | 1 | 2021 | 288 | 0.17 | Why? |
| Receptors, CCR5 | 1 | 2019 | 186 | 0.17 | Why? |
| Benzodioxoles | 1 | 2017 | 78 | 0.17 | Why? |
| Mathematics | 1 | 2017 | 65 | 0.17 | Why? |
| Masks | 1 | 2020 | 8528 | 0.17 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.16 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.16 | Why? |
| Heterozygote | 1 | 2017 | 249 | 0.16 | Why? |
| Geographic Mapping | 1 | 2017 | 247 | 0.16 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.16 | Why? |
| Hodgkin Disease | 1 | 2019 | 204 | 0.16 | Why? |
| England | 2 | 2018 | 5116 | 0.15 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.15 | Why? |
| Nicotine | 1 | 2019 | 213 | 0.15 | Why? |
| Victoria | 1 | 2018 | 607 | 0.15 | Why? |
| Ireland | 1 | 2021 | 1456 | 0.15 | Why? |
| Adolescent Health | 1 | 2019 | 227 | 0.15 | Why? |
| Child Behavior | 1 | 2019 | 266 | 0.15 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.14 | Why? |
| Female | 13 | 2021 | 380317 | 0.14 | Why? |
| Drug Costs | 1 | 2018 | 313 | 0.14 | Why? |
| Kenya | 1 | 2017 | 887 | 0.13 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.13 | Why? |
| Preventive Medicine | 1 | 2017 | 242 | 0.13 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.13 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.13 | Why? |
| Adolescent Behavior | 1 | 2019 | 400 | 0.12 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.12 | Why? |
| Human Rights | 1 | 2020 | 618 | 0.12 | Why? |
| General Practitioners | 1 | 2020 | 568 | 0.12 | Why? |
| Developed Countries | 1 | 2016 | 500 | 0.12 | Why? |
| Adaptation, Psychological | 2 | 2021 | 4996 | 0.12 | Why? |
| Delivery of Health Care | 1 | 2019 | 15909 | 0.12 | Why? |
| New South Wales | 1 | 2013 | 336 | 0.12 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.11 | Why? |
| Male | 11 | 2020 | 367725 | 0.11 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.11 | Why? |
| Spatial Analysis | 1 | 2017 | 878 | 0.11 | Why? |
| Africa | 1 | 2020 | 2986 | 0.11 | Why? |
| Weather | 1 | 2017 | 581 | 0.11 | Why? |
| United States | 4 | 2019 | 46150 | 0.11 | Why? |
| London | 1 | 2018 | 2166 | 0.11 | Why? |
| Respiration | 1 | 2016 | 729 | 0.11 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.11 | Why? |
| Allergens | 1 | 2017 | 728 | 0.11 | Why? |
| Pain | 1 | 2018 | 1084 | 0.10 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.10 | Why? |
| Singapore | 1 | 2020 | 3641 | 0.10 | Why? |
| Clinical Trials as Topic | 2 | 2020 | 7330 | 0.10 | Why? |
| Sex Distribution | 1 | 2017 | 2083 | 0.10 | Why? |
| Sweden | 1 | 2017 | 1969 | 0.10 | Why? |
| Tissue Donors | 1 | 2019 | 1679 | 0.10 | Why? |
| Infection Control | 1 | 2018 | 23131 | 0.10 | Why? |
| Indoles | 1 | 2017 | 1243 | 0.10 | Why? |
| Viral Load | 2 | 2019 | 15850 | 0.09 | Why? |
| Hospitalization | 1 | 2019 | 54280 | 0.09 | Why? |
| Mutation | 2 | 2019 | 12376 | 0.09 | Why? |
| Japan | 1 | 2021 | 6653 | 0.09 | Why? |
| Dengue | 1 | 2020 | 1565 | 0.09 | Why? |
| Child | 4 | 2019 | 70012 | 0.08 | Why? |
| South Africa | 1 | 2017 | 3326 | 0.08 | Why? |
| Adolescent | 4 | 2019 | 86841 | 0.08 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.08 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.08 | Why? |
| Research | 1 | 2019 | 2115 | 0.08 | Why? |
| International Cooperation | 1 | 2019 | 3436 | 0.07 | Why? |
| Neoplasms | 1 | 2013 | 17251 | 0.07 | Why? |
| Adult | 5 | 2021 | 244371 | 0.07 | Why? |
| State Medicine | 1 | 2018 | 2847 | 0.07 | Why? |
| Environmental Monitoring | 1 | 2016 | 3143 | 0.07 | Why? |
| Leadership | 1 | 2017 | 2241 | 0.07 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.06 | Why? |
| Europe | 1 | 2020 | 12702 | 0.06 | Why? |
| Health Status Disparities | 1 | 2020 | 4072 | 0.06 | Why? |
| Middle Aged | 4 | 2021 | 270681 | 0.05 | Why? |
| Developing Countries | 1 | 2016 | 4283 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.05 | Why? |
| India | 1 | 2017 | 11875 | 0.05 | Why? |
| Aged, 80 and over | 2 | 2019 | 88759 | 0.04 | Why? |
| Animals | 2 | 2018 | 78931 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2019 | 10083 | 0.04 | Why? |
| Mice | 1 | 2017 | 21357 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Italy | 1 | 2020 | 38444 | 0.04 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.04 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.03 | Why? |
| Prospective Studies | 1 | 2019 | 43301 | 0.03 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Risk Assessment | 1 | 2016 | 25439 | 0.03 | Why? |
| Aged | 2 | 2019 | 215776 | 0.03 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.03 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.02 | Why? |